A safe and effective short-course treatment regimen for post–kala-azar dermal leishmaniasis (PKDL) is considered essential for achieving and sustaining elimination of visceral leishmaniasis (VL) in the Indian subcontinent [1, 2]. Here, single-dose liposomal amphotericin B (AmBisome) has been adopted as a first-line regimen for VL; however the effectiveness and safety of AmBisome for PKDL has not been formally evaluated.

中文翻译：

---

短期AmBisome治疗Kala-Azar后皮肤利什曼病的安全性和有效性：孟加拉国的一项前瞻性队列研究

对于印度次大陆实现并持续消除内脏利什曼病（VL）而言，一种安全有效的短时间治疗黑热病后皮肤利什曼病（PKDL）的短程治疗方案必不可少[1，2]。在这里，单剂量脂质体两性霉素B（AmBisome）已被用作VL的一线治疗方案。但是，AmBisome对PKDL的有效性和安全性尚未得到正式评估。